Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ1 | P51787 | 6/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383477 | 1.00 | KCNQ1 (0.56) | KCNQ1HCRTR1HCRTR2POLBITGB1 | |
| SCHEMBL8269061 | 0.91 | POLB (0.53) | KCNQ1HCRTR1HCRTR2POLBITGB1 | |
| SCHEMBL13206972 | 0.91 | POLB (0.53) | KCNQ1HCRTR1HCRTR2POLBITGB1 | |
| SCHEMBL630004 | 0.91 | POLB (0.53) | KCNQ1HCRTR1HCRTR2POLBITGB1 | |
| SCHEMBL630680 | 0.90 | KCNQ1 (0.48) | KCNQ1HCRTR1HCRTR2POLBKMT2A | |
| SCHEMBL630210 | 0.89 | KCNQ1 (0.54) | KCNQ1HCRTR1HCRTR2POLBITGB1 | |
| SCHEMBL8266440 | 0.86 | HCRTR1 (0.43) | KCNQ1HCRTR1HCRTR2LMNAGAA | |
| SCHEMBL629838 | 0.86 | KCNQ1 (0.62) | KCNQ1HCRTR1HCRTR2POLBITGB1 | |
| SCHEMBL629837 | 0.86 | KCNQ1 (0.62) | KCNQ1HCRTR1HCRTR2POLBITGB1 | |
| SCHEMBL5173103 | 0.86 | KCNQ1 (0.62) | KCNQ1HCRTR1HCRTR2POLBITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | claimed |
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | FKBP1A, FKBP1B, FKBP3 | KCNQ1 4358/4885HCRTR1 1329/4885HCRTR2 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.